Jennifer Chien
Corporate Officer/Principal at RHYTHM PHARMACEUTICALS, INC.
Net worth: 261 404 $ as of 2024-04-29
Profile
Jennifer L.
Chien is currently the Executive Vice President & Head-North America at Rhythm Pharmaceuticals, Inc. Prior to this, she worked as the Vice President & Head-Genetic Diseases at Genzyme Therapeutics Ltd.
from 2017 to 2020.
She also briefly served as the Chief Commercial Officer at Krystal Biotech, Inc. in 2020.
Ms. Chien received her graduate degree from Harvard University and her undergraduate degree from Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-04-21 | 6,852 ( 0.01% ) | 261 404 $ | 2024-04-29 |
Jennifer Chien active positions
| Companies | Position | Start |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2020-11-08 |
Former positions of Jennifer Chien
| Companies | Position | End |
|---|---|---|
| KRYSTAL BIOTECH, INC. | Corporate Officer/Principal | 2020-10-15 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 2019-12-31 |
Training of Jennifer Chien
| Massachusetts Institute of Technology | Undergraduate Degree |
| Harvard University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| KRYSTAL BIOTECH, INC. | Health Technology |
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Jennifer Chien
